CNS biomarkers market growth outlook through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Central Nervous System Biomarkers Market Projected To Reach By 2030?
The central nervous system biomarkers market has exhibited robust growth in its size over recent years. It is projected to expand from $6.14 billion in 2025 to $6.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. The expansion during the past period can be ascribed to several factors, including the increasing occurrence of neurological disorders, advancements in neuroimaging and assay technologies, heightened clinical research activity within neurology, a rising need for disease progression monitoring, and the broader scope of biomarker validation studies.
The central nervous system biomarkers market is projected to experience swift expansion over the coming years. Its valuation is anticipated to reach $9.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This projected growth is primarily driven by heightened investments in precision neurology, the escalating application of biomarkers in personalized medical treatments, the broader embrace of AI-powered biomarker discovery, the widening scope of clinical trials guided by biomarkers, and the growing regulatory approval of biomarker endpoints. Key developments expected during this period involve the greater incorporation of blood-based central nervous system biomarkers, the increasing utility of biomarkers within drug development processes, an elevated emphasis on identifying neurodegenerative diseases at early stages, the proliferation of companion diagnostic biomarkers, and improved integration of multi-omics data.
Access Your Free Sample Report For In-Depth Market Analysis:
What Significant Factors Are Influencing The Central Nervous System Biomarkers Market Expansion?
An anticipated increase in neurological illnesses is projected to fuel the expansion of the central nervous system biomarker market in the future. Neurological illnesses, interchangeably called neurological disorders, encompass a wide spectrum of conditions impacting the brain, spinal cord, and the body’s entire nervous system. Such disorders can stem from diverse origins, such as genetic predispositions, infections, autoimmune reactions, degenerative conditions, tumor formations, vascular problems, and injuries resulting from trauma. Within the context of neurological disorders, central nervous system (CNS) biomarkers are instrumental in assisting clinical diagnosis, evaluating disease risk or prognosis, determining the stage of the illness, and monitoring the effectiveness of treatment. They are crucial for comprehending these conditions and their potential for therapeutic intervention. As an illustration, data from April 2023, provided by the US-based government agency, the Centers for Disease Control and Prevention, indicated that approximately 6.7 million Americans aged 65 and above were living with Alzheimer’s disease. This figure is projected to almost triple, reaching 14 million by 2060. Furthermore, the prevalence of individuals affected by the disease doubles every five years once they pass age 65. Consequently, the increase in neurological illnesses is a primary factor propelling the expansion of the central nervous system biomarker market.
How Are Segments Identified Within The Central Nervous System Biomarkers Market Segment Framework?
The central nervous system biomarkers market covered in this report is segmented –
1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users
Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression
What Trends Are Affecting The Direction Of The Central Nervous System Biomarkers Market?
Leading firms within the central nervous system biomarker sector are concentrating on developing and launching advanced solutions, including assay kits. An assay kit consists of a pre-assembled collection of reagents and other components for performing a particular scientific assessment. For example, in June 2023, Sysmex Corporation, a research and development company located in Japan, introduced an Automated Immunoassay System. This particular assay kit is engineered to detect the buildup of amyloid beta (Aß) in the brain, a known contributor to Alzheimer’s disease, by analyzing a minimal blood sample. It quantifies the proportion of Aß peptides present in the blood, utilizing an automated immunoassay system. This enables medical professionals to pinpoint Aß accumulation in the brain through a small blood sample, facilitating prompt diagnosis and therapeutic intervention for individuals.
Who Are The Companies Competing Within The Central Nervous System Biomarkers Market?
Major companies operating in the central nervous system biomarkers market are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Banyan Biomarkers Inc., Anavex Life Sciences Corp., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Avid Radiopharmaceuticals Inc., Cassava Sciences Inc.
Get The Full Central Nervous System Biomarkers Market Report:
Which Region Dominates The Central Nervous System Biomarkers Market By Market Share?
North America was the largest region in the central nervous system biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Central Nervous System Biomarkers Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Central Nervous System Biomarkers Market 2026, By The Business Research Company
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Neurological Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
